Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles

Katrin Bachelier¹, Susanne Biehl¹, Viktoria Schwarz¹, Ingrid Kindermann¹, Reinhard Kandolf², Martina Sauter², Christian Ukena¹, Ali Yilmaz³, Karen Sliwa⁴, Claus-Thomas Bock², Karin Klingel², Michael Böhm¹*

¹ Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/ Saar, Universität des Saarlandes, Saarlandes, Germany, ² Universitätsklinikum Tübingen, Abteilung Molekulare Pathologie, Institut für Pathologie und Neuropathologie, Tübingen, Germany, ³ Universitätsklinikum Münster, Department für Kardiologie und Angiologie, Münster, Germany, ⁴ Hatter Institute for Cardiovascular Research in Africa and MRC Inter-Cape Heart Group, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

* michael.boehm@uks.eu

Abstract

Background

Diagnosis of viral myocarditis is difficult by clinical criteria but facilitated by detection of inflammation and viral genomes in endomyocardial biopsies. Parvovirus B19 (B19V) targets endothelial cells where viral nucleic acid is exclusively detected in the heart. Microparticles (MPs) are released after cell damage or activation of specific cells. We aimed to investigate whether circulating endothelial MPs (EMPs) in human and experimental models of myocarditis are associated with B19V myocarditis.

Methods

MPs were investigated in patients with myocarditis (n = 54), divided into two groups: B19V+ (n = 23) and B19V- (n = 31) and compared with healthy controls (HCTR, n = 25). MPs were also investigated in B19V transgenic mice (B19V-NS1+) and mice infected with coxsackievirus B3 (CVB3). MPs were analyzed with fluorescent activated cell sorting (FACS).

Results

In human samples, EMP subpopulation patterns were significantly different in B19V+ compared to B19V- and HCTR (p<0.001), with an increase of apoptotic but not activated EMPs. Other MPs such as platelet- (PMPs) leukocyte-(L MPs) and monocyte-derived MPs (MMPs) showed less specific patterns. Significantly different levels of EMPs were observed in transgenic B19V-NS1+ mice compared with CVB3-infected mice (p<0.001).

Conclusion

EMP subpopulations are different in B19V+ myocarditis in humans and transgenic B19V mice reflecting vascular damage. EMP profiles might permit differentiation between
endothelial-cell-mediated diseases like myocardial B19V infection and other causes of myocarditis.

Introduction
Myocarditis is a non-ischemic inflammatory heart disease, which is potentially leading to severe heart failure and death [1,2]. Clinical manifestations vary with a broad spectrum from mild symptoms to cardiogenic shock [1–4], sometimes with the need for heart transplantation [5]. Myocarditis can result from common viral infections and post-viral immune-mediated responses [6]. Parvovirus B19 (B19V), a non-enveloped single-stranded DNA virus, belongs to the genus of erythroviruses, invades and replicates in erythroid precursor cells and endothelial cells [7]. Since diagnosis can be difficult, endomyocardial biopsy (EMB) with immunohistology is needed to define inflammation and molecular patterns in order to characterize the types of viral infection [8,9]. Many studies have detected B19V genomes in EMB from patients with acute and chronic myocarditis [10] with diastolic dysfunction [11] and peripartal [6] cardiomyopathy. The high prevalence of B19V (30–35%) in dilated cardiomyopathy (DCM) suggests that DCM could develop from previous B19V-associated myocarditis [11,12]. However, many individuals (80%) at the age of 60 carry B19V- that its specificity has been questioned [13]. It has been shown that cardiac endothelial cells (ECs) but not myocytes are the B19V-specific targets providing expression of the blood-group P-antigen serving as a cellular receptor for B19V [14] allowing persistence of B19V in ECs leading to endothelial cell apoptosis [15]. EMPs are released from cellular membranes during cell activation and apoptosis [16] and predict flow-mediated dilatation, cardiovascular events in rheumatoid arthritis [17] with endothelial dysfunction, predicts outcomes in acute coronary syndromes [18] and allow differentiating peripartal cardiomyopathy from normal pregnancy and other causes of heart failure [19]. It is unknown whether EMPs can differentiate among inflammatory cardiac diseases. We investigated circulating EMPs in patients with B19V+ and B19V- myocarditis to explore whether endothelial and myocardial damage can be distinguished. We compared the human findings with mouse models of transgenic B19V-NS1 mice or CVB3 myocarditis and controls.

Methods
Study design

Patients. Blood samples were obtained from patients with clinical evidence for myocarditis (n = 54), divided into two groups after endomyocardial biopsy (EMB), B19V+ (n = 23, EF 53±18%) and B19V- (n = 31, EF 46±21%) and then compared with healthy controls (HCTR, n = 25). All patients underwent left ventricular EMB and histological, immunohistological and molecular workup as previously described [5,9,19]. After informed consent, 10 ml peripheral venous blood was sampled from each of the 79 enrolled subjects. Demographic and clinical data are summarized in Table 1. Controls were age-matched volunteers who had no cardiovascular disease. They had been recruited during 2008–2009 for several studies. The study was approved by the appropriate ethics committee (Ethikkommission der Universität des Saarlandes, Nr. 122/09). All patients gave written informed consent to include their data in the study.

Generation of conditional transgenic B19V-NS1 mouse lines. B19V DNA was isolated from deparaffinized myocardial tissues of patients with fatal B19V-associated myocarditis as described previously to generate transgenic mice (accession no. AY768535 and AF162273)
Table 1. Clinical parameters of human samples.

|                           | B19V+ (n = 23) | B19V+ (p-value vs HCTR) | B19V- (n = 31) | B19V- (p-value vs HCTR) | HCTR (n = 25) |
|---------------------------|----------------|-------------------------|----------------|-------------------------|---------------|
| **Clinical Parameters**   |                |                         |                |                         |               |
| Mean Age [yrs] ± SD       | 55 ± 13        | 0.775                   | 60 ± 11        | 0.505                   | 51 ± 6        |
| Gender [m:w]              | 10:13          |                        | 21:10          |                          | 0:14          |
| **Virus infection (EMB)** |                |                         |                |                         |               |
| HHV6                      | 0              | -                       | 3              | -                       | -             |
| EBV                       | 0              | -                       | 1              | -                       | -             |
| B19V                      | 23             | -                       | 0              | -                       | -             |
| No Virus                  | 0              | -                       | 27             | -                       | -             |
| **Echocardiographic parameters** |            |                         |                |                         |               |
| LVEDD [mm]                | 62 ± 16        | 0.693                   | 64 ± 21        | 0.690                   | 53 ± 16       |
| LVESD [mm]                | 50 ± 14        | 0.409                   | 51 ± 15        | 0.456                   | 38 ± 5        |
| IVSD [mm]                 | 14 ± 6         | 0.610                   | 13 ± 2         | 0.409                   | 11 ± 1        |
| IVDD [mm]                 | 11 ± 4         | 0.820                   | 14 ± 3         | 0.297                   | 10 ± 2        |
| LVPWD [mm]                | 10 ± 4         | 0.820                   | 11 ± 3         | 1.000                   | 11 ± 2        |
| LVPS [mm]                 | 15 ± 3         | 0.245                   | 16 ± 2         | 0.103                   | 10 ± 3        |
| LVEF [mm]                 | 53 ± 18        | 0.313                   | 46 ± 21        | 0.251                   | 79 ± 18       |
| **Laboratory parameters** |                |                         |                |                         |               |
| CK [UI]                   | 155 ± 80       | 0.493                   | 132 ± 67       | 0.674                   | 99 ± 25       |
| CK-M [UI]                 | 45 ± 12        | 0.010                   | 41 ± 9         | 0.010                   | <14 ± 0       |
| ASAT [UI]                 | 85 ± 18        | 0.006                   | 55 ± 12        | 0.117                   | 32 ± 6        |
| ALAT [UI]                 | 90 ± 13        | 0.002                   | 48 ± 8         | 0.388                   | 37 ± 10       |
| LDH [UI]                  | 301 ± 267      | 0.601                   | 315 ± 210      | 0.527                   | 160 ± 75      |
| Creatinine [mg/dL]        | 1.12 ± 0.81    | 0.789                   | 1.21 ± 0.75    | 0.881                   | 1.34 ± 0.24   |
| Troponin [ng/mL]          | 1.6 ± 1.0      | 0.104                   | 1.2 ± 0.4      | 0.010                   | <0.01         |
| NT-Pro-BNP [pg/mL]       | 1498 ± 2526    | -                       | 2285 ± 1847    | -                       | 0 ± 0         |
| CRP [mg/mL]               | 46 ± 72        | -                       | 50 ± 11        | -                       | 0 ± 0         |

Basic characteristics of patients with DCM with positive EMB for B19V (B19V+), negative EMB for B19V (B19V-) and healthy controls (HCTR). LVEDD = left ventricular enddiastolic diameter, LVESD = left ventricular endsystolic diameter, IVSD = interventricular endsystolic diameter, IVDD = interventricular enddiastolic diameter, LVPWD = left ventricular posterior wall diameter, LVPS = left ventricular posterior septal diameter, FS = fractional shortening, LVEF = left ventricular ejection fraction, CK = creatine kinase, CK-M = creatine kinase muscle, ASAT = aspartate transaminase, ALAT = alanine transaminase, LDH = lactate dehydrogenase, NT-Pro-BNP = N-terminal pro brain natriuretic peptide, CRP = C-reactive protein, n.d. = not determined. Plus-minus values are means ± Standard Deviation (SD); LVEDD: Left ventricular enddiastolic diameter; LVESD: Left ventricular endsystolic diameter; IVSD: Interventricular endsystolic diameter; IVDD: Interventricular enddiastolic diameter; LVPWD: Left ventricular posterior wall diameter; LVPS: Left ventricular posterior septal diameter; LVEF: Left ventricular ejection fraction; CK: Creatinine kinase; CK-M: Creatine kinase muscle; ASAT: Aspartate transaminase; ALAT: Alanine transaminase; LDH: Lactate dehydrogenase; NT-Pro-BNP: N-terminal pro brain natriuretic peptide; CRP: C-reactive protein; HHV-6 human herpes virus type 6, EBV: Epstein-Barr virus, B19V: parvovirus B19

[20]. C57BL/6 mice were used for the generation of transgenic B19V mice (B19V-NS1) as well as control mice. For details refer to S1 Appendix.

**Murine CVB3 myocarditis.** CVB3 used in this study was derived from the infectious cDNA copy of the cardiotropic Nancy strain, and virus stocks were prepared as previously described [21]. C57BL/6 mice were infected with CVB3. Details can be found in S1 Appendix.

**Isolation of microparticles.** Microparticles were isolated as described previously [19]. Microparticles, vascular damage and parvovirus B19 myocarditis

https://doi.org/10.1371/journal.pone.0176311.t001
Statistical analysis

Data are expressed as mean ± standard error of the mean (SEM). Continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test and compared using a two-way ANOVA test, followed by a two-sided Bonferroni post-hoc testing. Tests for equal variance normality were performed using the Levene Median test. A p-value of <0.05 was considered statistically significant. Assumptions of normality and equal variance were automatically tested using the statistic program. Normal distribution of the parameters (NT-proBNP, CRP) was tested here using a Kolmogorov-Smirnov test. Both parameters showed normal distribution and are reported as mean +/- SD. Statistical analyses were performed using SigmaStat version 3.5. All data analyses and event classifications were performed by investigators blinded to the microparticle-status of patients and controls.

Results

The clinical and demographic data of the studied individuals are given in Table 1. FACS-analysis could be performed in all samples with myocarditis and were compared with healthy controls (n = 25). Controls had normal left ventricular fractional shortening and diameters without any differences between the groups. No significant differences occurred between B19 virus positive (B19V+) or negative (B19V-) hearts.

Human microparticles

**Endothelial MPs (EMPs).** Subpopulations of EMPs (CD144+) were significantly different in B19V+ compared to B19V- and HCTR (p<0.001, Fig 1A). The increase in B19V+ was due to an increase of apoptotic (Fig 1B, CD31+AV+) but not activated EMPs (Fig 1C, CD62E+) reflected in a lower CD62E/CD31 ratio (Table 2).

**Platelet-derived MPs (PMPs).** PMPs (CD62P+CD42b+AnnexinV+) increased in B19V+ compared to B19V- patients and healthy controls (HCTR, p<0.001, S1A Fig). PMPs in B19V- negative patients were similar in healthy controls. Apoptotic PMPs were significantly increased in B19V+ compared to B19V- (p<0.001) and to healthy controls (p<0.024) (S1B Fig). Activated PMPs were slightly elevated in B19V- compared with B19V+ (p = 0.004) and HCTR (p = 0.001), as demonstrated in S1C Fig. In B19V+, activated PMPs were slightly altered in comparison with HCTR (p = 0.023).

**Monocyte MPs (MMPs) and leukocyte MPs (LMPs).** MMPs (CD14+AnnexinV+) were increased in both, B19V+ and B19V- in contrast to healthy controls (p<0.001 and p<0.003, S2A Fig) without significance between themselves. LMPs (CD45+AnnexinV+) were significantly increased in B19V+ compared to B19V- (p<0.011) and healthy controls (p<0.004) as seen in S2B Fig.

Microparticles in mice

**Endothelial MPs (EMPs).** EMPs measured in C57BL/6 control mice compared to conditional transgenic B19V-NS1-mice without induction by doxycyclin as negative control were not changed (p = 0.755, Fig 2A). EMPs significantly increased in transgenic B19V-NS1 mice 2, 4 and 6 weeks after induction with doxycycline compared to controls (C57BL/6, p<0.001, Fig 2A) and B19V-NS1-mice without doxycyclin (p<0.001, p = 0.003 and p = 0.029, Fig 2A). The increase had its maximum after two weeks (8.3 ± 0.14 x103/ml) with a decline after four weeks (Fig 2A). Changing of EMPs was due to apoptotic EMPs as shown in Fig 3B and not to activated EMPs (Fig 2C).
Table 2. CD62 / CD31 ratio in endothelial microparticles.

|          | CD62E / CD31 Ratio SEM | p-value vs. control | p-value vs. max. of apoptosis |
|----------|------------------------|---------------------|------------------------------|
| Humans   |                        |                     |                              |
| B19V+    | 0.4 ± 0.8              | <0.001              | -                            |
| B19V-    | 1.4 ± 0.2              | 1.000               | <0.001                       |
| HCTR     | 1.4 ± 0.1              | -                   | <0.001                       |
| Mice     |                        |                     |                              |
| C57 / BL6| 1.4 ± 0.9              | -                   | 0.040                        |
| B19V no Doxy | 1.4 ± 1.1 | 1.000               | 0.066                        |
| B19V+ 2wks | 0.3 ± 0.7 | 0.040               | -                            |
| B19V+ 4wks | 0.8 ± 0.2 | 0.115               | 0.123                        |
| B19V+ 6wks | 0.9 ± 0.2 | 0.240               | 0.071                        |

CD62E/CD31-ratio is used as an index of activation (high ratio, >4) or apoptosis (low ratio, <0.4) for distinguishing between apoptotic or activated EMP generation. The increase of EMPs in our study, either in humans or mice, was due to significantly elevated apoptotic EMPs (CD31+) and not activated EMPs (CD62E+) reflected by the lower CD62E+/CD31-ratio. In CBV3+ samples the highest maximum of apoptosis was shown to be after 2 days post infection whereas it was reached in B19V+ 2 weeks after induction. Comparing the maximums of both groups transgenic B19V-NS1-mice with induction by doxycycline demonstrated a significant ratio (p = 0.004) indicating a higher endothelial apoptosis. MP = microparticles, EMPs = Endothelial microparticles, PMP = Platelet-derived microparticles, MMPs = Monocyte microparticles, LMPs = Leucocyte microparticles, m = mean, SD = standard error.

https://doi.org/10.1371/journal.pone.0176311.t002
Murine Endothelial Microparticles (B19V+)

A All

C57/BL6  B19V+ noDox  B19V+ Doxy2wks  B19V+ Doxy4wks  B19V+ Doxy6wks

EMPs [CD144+](*x1000/mm³)

B Apoptotic

C57/BL6  B19V+ noDox  B19V+ Doxy2wks  B19V+ Doxy4wks  B19V+ Doxy6wks

Apoptotic EMPS [CD31+](*x1000/mm³)

C Activated

C57/BL6  B19V+ noDox  B19V+ Doxy2wks  B19V+ Doxy4wks  B19V+ Doxy6wks

Activated EMPS [CD62E+/Annexiv+](*x1000/mm³)

Fig 2. Murine endothelial microparticles (B19V- transgenic mice). Murine endothelial microparticles (EMPs) in transgenic B19V-NS1-mice with induction by doxycycline (B19V+) after 2, 4 and 6 weeks p.i.
Mice infected with coxsackievirus B3 (CVB3) were studied for comparison. A small increase of EMPs was detectable in CVB3-infected mice at the early stage of infection (2 days p.i. (6.19 ± 0.5 x10^3/ml, p<0.001 vs. control) with a rapid decline during acute infection at 8 days p.i. later at 28 days p.i. (Fig 3). Comparing both model systems, EMPs were significantly more increased in B19V-NS1-mice compared to CVB3-infected mice 2 days p.i. (p = 0.009, not shown).

Other MPs. PMPs measured in C57BL/6 control mice compared to transgenic B19V-NS1-mice without doxycyclin showed comparable levels (p = 0.463, not shown). PMP of B19V-NS1 after induction and of CVB3 mice after infection did not rise significantly (not shown). MMPs and LMPs measured in C57BL/6 control mice compared to transgenic B19V-NS1-mice without doxycyclin showed about the same levels (p = 0.768, not shown).

EMP apoptosis and activation. The ratio of CD62E/CD31 EMPs reflects endothelial activation versus apoptosis. The changed patterns of EMPs in humans (Fig 1) or mice (Fig 2) was due to significantly elevated apoptotic EMPs (CD31+) and not activated EMPs (CD62+). This is shown by the lower CD62/CD31 ratio (Table 2). Induced transgenic B19V-NS1-mice demonstrated a significantly elevated ratio (p = 0.004, Table 2) indicating a higher endothelial apoptosis compared to human B19+ hearts.

Discussion

EMP patterns were changed in humans with B19V myocarditis and in transgenic B19V-mice compared to healthy controls and control mice, respectively. In CVB3-infected mice, there were no or minor changes in EMPs, but increased levels of LMPs.

B19V DNA is the most frequent viral genome observed in endomyocardial biopsies (EMBs) with left ventricular dysfunction [2,11]. Previously, we found that myocardial endothelial cells but not myocytes are B19V-specific target cells [22]. B19V infects endothelial cells of small myocardial blood vessels resulting in impairment of myocardial endothelial dysfunction and impairing myocardial microcirculation [23,24]. Consistently, the presence of B19V-viral genome was associated with endothelial dysfunction and diastolic dysfunction [11] in patients with clinical signs of myocarditis. Patients can present with coronary vasospasm and atypical chest pain in patients with clinical signs of myocarditis and biopsy-proven myocarditis with virus persistence in the absence of significant coronary artery disease [25]. Herein, we found changed patterns of EMPs as a detectable marker reflecting endothelial damage, which were elevated in B19V+ patients but not in patients with B19V- myocarditis.

In order to add plausibility, we investigated transgenic B19V mice. Also, in this B19V associated model, an increase of EMPs was detected. It was accompanied by high levels of platelet-derived PMPs and LMPs, which could reflect the response to vascular damage reflected by significantly elevated EMPs. It is known that PMPs generated from apoptotic human platelets induce human monocyte chemotaxis and polarization into resident M2 monocytes, implying that these MPs possess immunomodulating properties [26]. MPs could act as signal transducers taking a critical role in mediating autoimmunity processes in the heart [27]. Activation or apoptosis of endothelial cells can lead to specific MP type formation, which can be
Murine Endothelial Microparticles (CVB3+)

A All

EMPs [CD144+]

C57/Bl6  CVB+2pi  CVB+8pi  CVB+28pi

B Apoptotic

Apoptotic EMPs [CD31+/Annexin-V+]

C57/Bl6  CVB+2pi  CVB+8pi  CVB+28pi

C Activated

Activated EMPs [CD62E+/Annexin-V+]

C57/Bl6  CVB+2pi  CVB+8pi  CVB+28pi

Fig 3. Murine endothelial microparticles (CVB3+ infected mice). Murine endothelial microparticles (EMPs) in CVB3+ infected mice (CVB3+) after 2, 8 and 28 days p.i. compared with controls (C57/Bl6). A:
differentiated by their specific marker expression patterns. The increased CD62E/CD31 ratio reported herein, suggests that apoptosis is an important mechanism for EMP release in B19V-induced heart disease.

In comparison to the murine model of B19V-induced heart disease, CVB3-infected mice showed higher levels of LMPs. CVB3 is known to infect primarily cardiomyocytes, and due to extensive virus replication, a rapid cytolysis of these cells occurs. Before reaching their cardiac target cells, the cardiomyocytes, CVB3 transmigrates through the endothelium for a short period of time during viremia [28]. The rise of EMPs in CVB3-infected mice observed in our study is likely reflecting diapedesis with penetration of virus through endothelial layers and affection of endothelial cells leading to a temporary vascular damage [28]. Subsequent antiviral immune responses might be an explanation for the activation of other MP types in these animals. Our measurements of MPs in CVB3-infected mice revealed a significant increase of inflammatory MPs such as MMPs and LMPs during acute myocarditis (8 days p.i) staying at higher levels at later stages of the disease (28 days p.i). MCP-1 is known to mediate migration of monocytes into virus-affected sites [29]. Elevation of MCP-1 levels at the initial presentation in patients with acute myocarditis was significantly correlated with the severity and prognosis [30]. The high levels of MMPs in our study are in agreement with the known activation of monocytes in the inflammatory response.

One limitation of the present study is the absence of coxsackievirus B infection in humans in this study. Unfortunately, human samples with CVB-myocarditis are rare. Therefore, the murine model of CVB3 myocarditis was used as it reflects human enteroviral myocarditis with regard to myocardial damage and virus-induced immune response [31]. Endomyocardial biopsies are usually taken in these patients at different time points after onset of myocarditis. Therefore, we cannot reconstruct the timing of the phases of inflammatory myocardial disease in our patients. The severity and outcome of the disease in different mouse models as well as the relative contributions of direct viral and inflammation-mediated mechanisms to the pathogenesis of the disease show apparently the same high variability as seen in humans [30].

Finally, we cannot exactly define whether the changed EMP patterns are derived from, the heart or also from the peripheral circulation. Since B19V infection is a systemic disease, apoptotic EMPs could also be derived from other compartments than the heart.

Our data provide first evidence that differential endothelial microparticle changes are detected in different virus-associated heart diseases. Differences in the subtypes of MPs can be attributed to specific myocardial virus infections targeting different cell types. B19V persists in the endothelium [15] and, thus, induces endothelial damage, while CVB3 targets myocytes and shows less pronounced transient endothelial reactions [25,28]. Both viral infections can finally lead in chronic myocardial disease and myocardial fibrosis with end-stage heart failure [6]. However, independently from the responsible virus leading to myocarditis, apoptotic processes are involved as indicated via AnnexinV positive MPs, which are detectable in CVB3- and B19V- induced myocarditis. Taken together, these data strengthen the notion that apoptosis may play a pivotal role in acute and chronic myocarditis. There is an increased awareness of the importance of myocarditis being a meaningful cause for DCM and heart failure. Substantial progress in diagnosis and management has been made over the past decade. However, myocarditis remains a diagnosis of exclusion and diagnosis is often delayed with consecutive late initiation of arising therapies like immunosuppressive or antiviral treatment [32].

https://doi.org/10.1371/journal.pone.0176311.g003

EMPs were increased in CVB3+ mice two days p.i. (p < 0.001 vs. control) with a decline in the following 6 days (p < 0.001 vs. control) and 28 days p.i. (p < 0.001 vs. control). B: The increase of EMPs was due to apoptotic EMPs. C: Activated EMPs were not different between the groups.
context and in the light of unreliable serodiagnostic [33], there is a clinical need for diagnostic biomarkers. Microparticle profiling could potentially become a valuable tool facilitating earlier diagnosis. EMPs are derived from extracellular vesicles, which are not only presenting debris from cellular damage, but are carrying proteincytokines, MRAs and non-coding MRAs to other target cells and, thus, are presenting one mechanism of intracellular communication. Future researches will have to address not only their patterns and different etiologies of inflammatory myocardial disease, but their function which could relate a progression of myocardial disease, but also protective mechanisms [34,35].

It is concluded that microparticle profiles vary between different myocardial diseases and could facilitate early differential diagnosis between endothelial-cell-mediated disease due to B19V and other causes of myocarditis and pave the way to early diagnoses and potentially to early initiation of treatment.

Supporting information

S1 Appendix. Methods.
(DOCX)

S1 Fig. Human platelet-derived microparticles (PMPs). Human platelet-derived microparticles (PMPs) in patients with myocarditis divided into B19+ and B19V- patients and compared with age-matched healthy controls (HCTR). The B19V- group consisted of either no virus detection or HHV6+ and EBV+ samples. A: PMPs were significantly increased in B19V+ patient samples compared to B19V- and HCTR. B19V- had increased EMP levels as well, but not significant versus HCTR. B: CD42b-AV+ PMPs represent apoptotic PMPs. Apoptotic PMPs were significantly higher detectable than activated PMPs in B19V+ and B19V-. C: CD62P+ PMPs represent activated PMPs.
(TIFF)

S2 Fig. Circulating inflammatory MPs. Monocyte-derived microparticles (MMPs,A) and leucocyte-derived microparticles (LMPs,B) in patients with myocarditis divided into B19V+ and B19V- patients and then compared with age-matched healthy controls (HCTR). The B19V-group consisted of either no virus detection or HHV6+ and EBV+ samples. A: MMPs were increased in both, B19V+ and B19V - in contrast to healthy controls (p<0.001 and p<0.003) but no significance between themselves. B: LMPs were significantly increased in B19V+ compared to B19V- (p<0.011) and healthy controls (p<0.004).
(TIFF)

Acknowledgments

Katrin Bacheler, Ingrid Kindermann and Michael Böhm were supported by the Ministry of Science and Economy of the Federal State of the Saarland and the HOMFOR-program. Michael Böhm was supported by the Deutsche Forschungsgemeinschaft (KFO 196). Karen Sliwa receives support grants from the South African National Research Foundation, the South African Medical Research Foundation and the BMBF on Cardiac disease in pregnancy including various forms of cardiomyopathies. Karin Klingel was supported by the Deutsche Forschungsgemeinschaft (SFB-TR19 and KL 595/2-3).

Author Contributions

Conceptualization: KB.
Data curation: KB MB.
Formal analysis: KB.
Funding acquisition: KB MB.
Investigation: KB SB VS.
Methodology: KB KK.
Project administration: KB MB.
Resources: AY MS C-TB KK.
Software: KB.
Supervision: KK C-TB AY RK KS MS IK.
Validation: CU.
Visualization: SB VS IK RK KS MS C-TB KK CU.
Writing – original draft: KB.
Writing – review & editing: MB.

References
1. Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360:1526–38. https://doi.org/10.1056/NEJMra0800028 PMID: 19357408
2. Caforio AL, Parkuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thieme G, Yilmaz A, Charron P, Elliott PM: European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34:2636–48, 2648A-2648. https://doi.org/10.1093/eurheartj/eht210 PMID: 23824828
3. McCarthy RE 3rd, Boehm JP, Hutchins GM, Kasper EK, Hare JM, Baughman KL. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342:690–6. https://doi.org/10.1056/NEJM200003093421003 PMID: 10706898
4. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, Klingel K, Kandolf R, Sechtem U, Cooper LT, Böhm M. Update on myocarditis. J Am Coll Cardiol 2012; 59:779–92. https://doi.org/10.1016/j.jacc.2011.09.074 PMID: 22361396
5. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, Lindinger A, Böhm M. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118:639–48. https://doi.org/10.1161/CIRCULATIONAHA.108.769489 PMID: 18645053
6. Büttermann BD, Klingel K, Nabauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 2005; 193:363–5. https://doi.org/10.1016/j.ajog.2005.01.022 PMID: 16098856
7. Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, Caul O, Dieppe PA. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149:1153–6. PMID: 2541666
8. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R; American Heart Association; American College of Cardiology; European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007; 116:2216–33. https://doi.org/10.1161/CIRCULATIONAHA.107.186093 PMID: 17959655
9. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, Hill S, Mahroldt H, Voehringer M, Schieber M, Klingel K, Kandolf R, Böhm M, Sechtem U. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010; 122:900–9. https://doi.org/10.1161/CIRCULATIONAHA.109.924167 PMID: 20713901
10. Parkuweit S, Moll R, Baandrup U, Portig I, Hufnagel G, Maisch B. Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol 2003; 34:497–503. PMID: 12792925
11. Tschope C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmeck PL, Pauschinger M, Poller WC, Kühl U, Kandolf R, Schultheiss HP. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111:879–86. https://doi.org/10.1161/01.CIR.0000156561.68924.B3 PMID: 15710767

12. Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss HP. Prevalence of erythroivirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol 2008; 80:1243–51. https://doi.org/10.1002/jmv.21187 PMID: 18461615

13. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15:485–505. https://doi.org/10.1128/CMR.15.3.485-505.2002 PMID: 12097253

14. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993; 262:114–7. PMID: 8211117

15. Schmidt-Lucke C, Spillmann F, Bock T, Kühl U, Van Linthout S, Schultheiss HP, Tschope C. Interferon beta modulates endothelial damage in patients with cardiac persistence of human parvovirus b19 infection. J Infect Dis 2010; 201:936–45. https://doi.org/10.1086/650700 PMID: 20158391

16. Jimenez J, Wy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003; 109:175–180. PMID: 12757771

17. Kniff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002; 6:1498–503.

18. Sinning JM, Losch J, Walenta K, Böhm M, Nickenig G, Werner N. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2011; 32:2034–41. https://doi.org/10.1093/eurheartj/ehq478 PMID: 21186238

19. Walenta K, Schwarz V, Schirmer S, Kindermann I, Friedrich EB, Solomayer EF, Sliwa K, Labidi S, Hilliker-Kleiner D, Böhm M. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J 2012; 33:1469–74. https://doi.org/10.1093/eurheartj/ehq485 PMID: 22307461

20. Duechting A, Tschope C, Kaiser H, Lam kerneyer T, Tanaka N, Aberle S, Lang F, Torresi J, Kandolf R, Bock CT. Human parvovirus b19 ns1 protein modulates inflammatory signaling by activation of stat3/pias3 in human endothelial cells. J Virol 2008; 82:7942–7952. https://doi.org/10.1128/JVI.00891-08 PMID: 18550668

21. König K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, Kandolf R. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA. 1992; 89:314–318. PMID: 1309611

22. Bültmann BD, König K, Sotlar K, Bock CT, Baba HA, Sauter M, Kandolf R. Fatal parovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum Pathol 2003; 34:92–5. https://doi.org/10.1016/S0046-8177(02)00732-8 PMID: 12605372

23. Bültmann BD, König K, Sotlar K, Bock CT, Kandolf R. Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch 2003; 442:8–17. https://doi.org/10.1007/s00428-002-0732-8 PMID: 12536309

24. Bock CT, König K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010; 362:1246–1249. https://doi.org/10.1056/NEJMoa0911362 PMID: 20357294

25. Vallbracht KB, Schwimmeck PL, Kühl U, Seeberg B, Schultheiss HP. Endothelium-dependent flow-mediated vasodilatation of systemic arteries is impaired in patients with myocardial virus persistence. Circulation 2004; 110:2938–2945. https://doi.org/10.1161/01.CIR.0000146891.31481.CF PMID: 15505098

26. Vasina EM, Cauwenberghs S, Feijge MA, Heemskerk JW, Weber C, Koenen RR. Microparticles from apoptotic platelets promote resident macrophage differentiation. Cell Death Dis 2011; 2:E211. https://doi.org/10.1038/cddis.2011.94 PMID: 21956548

27. Pisetsky DS, Lipsky PE. Microparticles as autoadjuvants in the pathogenesis of SLE. Nat Rev Rheumatol 2010; 6:368–72. https://doi.org/10.1038/nrrheum.2010.66 PMID: 20458331

28. König K, Rieger P, Mall G, Selinka HC, Huber M, Kandolf R. Visualization of entoviral replication in myocardial tissue by ultrastructural in situ hybridization: identification of target cells and cytopathic effects. Lab Invest 1998; 78:1227–37. PMID: 9800948

29. Rollins BJ. Monocyte chemoattractant protein-1: a potent regulator of monocyte recruitment in inflammmatory disease. Mol Med Today 2000; 6:198–204. PMID: 10732836

30. Fuse K, Kodama M, Hanawa H, Okura Y, Ito M, Shiono T, Maruyama S, Hiroto S, Kato K, Watanabe K, Azawaya Y. Enhanced expression and production of monocyte chemoattractant protein-1 in myocarditis. Clin Exp Immunol 2001; 124:346–52. https://doi.org/10.1046/j.1365-2249.2001.01510.x PMID: 11472393
31. Klingel K, Kandolf R. The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand J Infect Dis Suppl 1993; 88: 79–85. PMID: 8390720

32. Schultheiss HP, Piper C, Sowade O, Waagstein F, Kapp JF, Wegscheider K, Groetzbach G, Pauschinger M, Escher F, Arbustini E, Siedentop H, Kühn U. Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy. Clin Res Cardiol 2016; 105:763–73. https://doi.org/10.1007/s00392-016-0986-9 PMID: 27112783

33. Mahfoud F, Gärtner B, Kindermann M, Ukena C, Gadomski K, Klingel K, Kandolf R, Böhm M, Kindermann I. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011; 32:897–903. https://doi.org/10.1093/eurheartj/ehq493 PMID: 21217143

34. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol 2011; 31:27–33. https://doi.org/10.1161/ATVBAHA.110.218123 PMID: 21160065

35. Lawson C, Vicencio JM, Yellon DM, Davidson SM. Microvesicles and exosomes: new players in metabolic and cardiovascular disease. J Endocrinol 2016; 228:R57–71. https://doi.org/10.1530/JOE-15-0201 PMID: 26743452